Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Schofield
“Vested interests” are pressuring EU policymakers to water down further European Commission plans for an exemption intended to allow generic and biosimilar firms to manufacture their versions of products for export while SPCs are still in effect, claims the industry sector body Medicines for Europe.
Mike Thompson, head of the Association of the British Pharmaceutical Industry, outlined his industry’s concerns over medicines stockpiling, batch testing, tariffs, regulatory collaboration and other issues at a parliamentary committee hearing on the implications of a no-deal Brexit.